Shots:
- Insilico Medicine and Tenacia Biotechnology have expanded their AI-driven R&D collaboration to develop an additional CNS candidate with defined properties, advancing it to the preclinical candidate stage for neurological disorders
- The initial collaboration, launched in Mar 2025, combined Insilico’s Pharma.AI platform with Tenacia’s CNS expertise to develop BBB-permeable small-molecule inhibitors, with the program progressing smoothly
- As per the expanded agreement, Insilico is eligible for near-term & milestone payments, with total potential deal value of up to ~$94.75M, as both companies aim to reduce late-stage risk & enhance clinical outcomes in complex neurological diseases
Ref: PRnewswire| Image: Insilico & Tenacia | Press Release
Related News: Insilico Medicine and CMS Enter Multiple Collaborations to Advance Therapeutics in CNS and Autoimmune Indications
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
